[Supportive options in the treatment of urological tumours].
An ageing society with a consecutive increase of genitourinary malignancies along with remarkable changes in systemic cancer therapy provide the basis for an increasing role of supportive measures. While surgical treatment, radiation or chemotherapy are undergoing subsequent standardisation, supportive measures are still widely used on the basis of personal experience alone. However, effective support is the prerequisite for a successful systemic treatment. Within this review the most relevant side effects of systemic therapy for urological tumors are summarised and the respective therapeutic options are presented in a brief but practice-oriented way. The authors have aimed at the consideration of evidence-based measures, wherever possible.
Urologie, EuromedClinic, Fürth, Deutschland.
B J
BJ
Schmitz-Dräger
E
E
Bismarck
C
C
Fischer
D000970:Antineoplastic Agents / Q000627:therapeutic use* / Q000633:toxicity*; D019317:Evidence-Based Medicine; D006801:Humans; D010166:Palliative Care / Q000379:methods*; D012307:Risk Factors; D014565:Urogenital Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents